Rabies DNA vaccine - LigoCyte/NIAID

Drug Profile

Rabies DNA vaccine - LigoCyte/NIAID

Latest Information Update: 05 Aug 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LigoCyte Pharmaceuticals; National Institute of Allergy and Infectious Diseases
  • Class Gene therapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rabies

Most Recent Events

  • 05 Aug 2004 Discontinued - Preclinical for Rabies in USA (IM)
  • 12 Jan 2004 No development reported - Preclinical for Rabies in USA (IM)
  • 05 Oct 2001 LigoCyte has entered into a CRADA with the NIAID for development of the rabies vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top